Cargando…

Circulating monocytes accelerate acute liver failure by IL‐6 secretion in monkey

Acute liver failure (ALF) is associated with high mortality, and a poor understanding of the underlying pathophysiology has resulted in a lack of effective treatments so far. Here, using an amatoxin‐induced rhesus monkey model of ALF, we panoramically revealed the cellular and molecular events that...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Gang, Zhu, Yongjie, Wu, Zhenru, Ji, Hongjie, Lu, Xufeng, Zhou, Yongjie, Li, Yuanmin, Cao, Xiaoyue, Lu, Yanrong, Talbot, Prue, Liao, Jiayu, Shi, Yujun, Bu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6111866/
https://www.ncbi.nlm.nih.gov/pubmed/29992739
http://dx.doi.org/10.1111/jcmm.13673
Descripción
Sumario:Acute liver failure (ALF) is associated with high mortality, and a poor understanding of the underlying pathophysiology has resulted in a lack of effective treatments so far. Here, using an amatoxin‐induced rhesus monkey model of ALF, we panoramically revealed the cellular and molecular events that lead to the development of ALF. The challenged monkeys with toxins underwent a typical course of ALF including severe hepatic injury, systemic inflammation and eventual death. Adaptive immune was not noticeably disturbed throughout the progress of ALF. A systematic examination of serum factors and cytokines revealed that IL‐6 increase was the most rapid and drastic. Interestingly, we found that IL‐6 was mainly produced by circulating monocytes. Furthermore, ablation of monocyte‐derived IL‐6 in mice decreased liver injury and systemic inflammation following chemical injection. Our findings reveal a critical role of circulating monocytes in initiating and accelerating ALF, indicating a potential therapeutic target in clinical treatment for ALF.